-
Mashup Score: 1
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its prior HER2-low indication.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
FDA reviews biologics license application for HLX11, a biosimilar to pertuzumab, for HER2-positive breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The #FDA accepted for review a biologics license application seeking the approval of HLX11 for the treatment of select patients with HER2+ breast cancer. #bcsm https://t.co/PhtM5MMlVM
-
-
Mashup Score: 5
Virginia G. Kaklamani, MD, DSc, discusses findings from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
#FDA Approves Dato-DXd in HR+, HER2- Breast Cancer Following TROPION-Breast01 | #bcsm @VKaklamani https://t.co/IQySV04avy
-
-
Mashup Score: 4
Providers advised to halt use, monitor patients, and report any complications with BioZorb devices to the FDA.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The #FDA has warned against using BioZorb Markers due to potential adverse effects, following Hologic’s recall of all unused devices. #bcsm https://t.co/0sLcho93Mh
-
-
Mashup Score: 1
The application is supported by results from the phase III DESTINY-Breast06 trial.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has granted a priority review to trastuzumab deruxtecan for unresectable or metastatic HER2-low or HER2-ultralow breast cancer after at least one endocrine therapy in the metastatic setting. #FDA #bcsm https://t.co/gvlNFQqkEL
-
-
Mashup Score: 0
Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and III early breast cancer at a high risk of recurrence.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
BREAKING: The #FDA has approved adjuvant ribociclib + an aromatase inhibitor in hormone receptor-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence. #bcsm | @UCLAHealth https://t.co/5QJkiWNfvP https://t.co/UBG1RyugYK
-
-
Mashup Score: 0
Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and III early breast cancer at a high risk of recurrence.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
BREAKING: The #FDA has approved adjuvant ribociclib + an aromatase inhibitor in hormone receptor-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence. #bcsm | @UCLAHealth https://t.co/5QJkiWNfvP https://t.co/UBG1RyugYK
-
-
Mashup Score: 0
Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and III early breast cancer at a high risk of recurrence.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
BREAKING: The #FDA has approved adjuvant ribociclib + an aromatase inhibitor in hormone receptor-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence. #bcsm | @UCLAHealth https://t.co/5QJkiWNfvP https://t.co/UBG1RyugYK
-
-
Mashup Score: 0
Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and III early breast cancer at a high risk of recurrence.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
BREAKING: The #FDA has approved adjuvant ribociclib + an aromatase inhibitor in hormone receptor-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence. #bcsm | @UCLAHealth https://t.co/5QJkiWNfvP https://t.co/UBG1RyugYK
-
-
Mashup Score: 6
The breakthrough therapy designation is supported by findings from the phase 3 DESTINY-Breast06 study comparing the antibody-drug conjugate with chemotherapy in patients with HR+/HER2-low breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The #FDA has granted breakthrough therapy designation to trastuzumab deruxtecan in unresectable or metastatic HR+/HER2-low or HER2-ultralow breast cancer. #BCSM https://t.co/NyS9CFB71p
-
The #FDA has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) assay, allowing for the identification of patients with HR-positive, HER2-ultralow metastatic breast cancer who may benefit from T-DXd. #bcsm https://t.co/8Bm3MyAcwb